Table of Content

Table of Contents
1 RESEARCH SCOPE
1.1 Research Product Definition
1.2 Research Segmentation
1.2.1 Product Type
1.2.2 Main product Type of Major Players
1.3 Demand Overview
1.4 Research Methodology
2 GLOBAL PYELONEPHRITIS DRUG INDUSTRY
2.1 Summary about Pyelonephritis Drug Industry
2.2 Pyelonephritis Drug Market Trends
2.2.1 Pyelonephritis Drug Production & Consumption Trends
2.2.2 Pyelonephritis Drug Demand Structure Trends
2.3 Pyelonephritis Drug Cost & Price
3 MARKET DYNAMICS
3.1 Manufacturing & Purchasing Behavior in 2020
3.2 Market Development under the Impact of COVID-19
3.2.1 Drivers
3.2.2 Restraints
3.2.3 Opportunity
3.2.4 Risk
4 GLOBAL MARKET SEGMENTATION
4.1 Region Segmentation (2017 to 2021f)
4.1.1 North America (U.S., Canada and Mexico)
4.1.2 Europe (Germany, UK, France, Italy, Rest of Europe)
4.1.3 Asia-Pacific (China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific)
4.1.4 South America (Brazil,, Argentina, Rest of Latin America)
4.1.5 Middle East and Africa (GCC, North Africa, South Africa, Rest of Middle East and Africa)
4.2 Product Type Segmentation (2017 to 2021f)
4.2.1 Finafloxacin
4.2.2 Fosfomycin Tromethamine
4.2.3 Nacubactam
4.2.4 Plazomicin Sulfate
4.2.5 Others
4.3 Consumption Segmentation (2017 to 2021f)
4.3.1 Hospital
4.3.2 Clinic
4.3.3 Others
5 NORTH AMERICA MARKET SEGMENT
5.1 Region Segmentation (2017 to 2021f)
5.1.1 U.S.
5.1.2 Canada
5.1.3 Mexico
5.2 Product Type Segmentation (2017 to 2021f)
5.2.1 Finafloxacin
5.2.2 Fosfomycin Tromethamine
5.2.3 Nacubactam
5.2.4 Plazomicin Sulfate
5.2.5 Others
5.3 Consumption Segmentation (2017 to 2021f)
5.3.1 Hospital
5.3.2 Clinic
5.3.3 Others
5.4 Impact of COVID-19 in North America
6 EUROPE MARKET SEGMENTATION
6.1 Region Segmentation (2017 to 2021f)
6.1.1 Germany
6.1.2 UK
6.1.3 France
6.1.4 Italy
6.1.5 Rest of Europe
6.2 Product Type Segmentation (2017 to 2021f)
6.2.1 Finafloxacin
6.2.2 Fosfomycin Tromethamine
6.2.3 Nacubactam
6.2.4 Plazomicin Sulfate
6.2.5 Others
6.3 Consumption Segmentation (2017 to 2021f)
6.3.1 Hospital
6.3.2 Clinic
6.3.3 Others
6.4 Impact of COVID-19 in Europe
7 ASIA-PACIFIC MARKET SEGMENTATION
7.1 Region Segmentation (2017 to 2021f)
7.1.1 China
7.1.2 India
7.1.3 Japan
7.1.4 South Korea
7.1.5 Southeast Asia
7.1.6 Australia
7.1.7 Rest of Asia Pacific
7.2 Product Type Segmentation (2017 to 2021f)
7.2.1 Finafloxacin
7.2.2 Fosfomycin Tromethamine
7.2.3 Nacubactam
7.2.4 Plazomicin Sulfate
7.2.5 Others
7.3 Consumption Segmentation (2017 to 2021f)
7.3.1 Hospital
7.3.2 Clinic
7.3.3 Others
7.4 Impact of COVID-19 in Europe
8 SOUTH AMERICA MARKET SEGMENTATION
8.1 Region Segmentation (2017 to 2021f)
8.1.1 Brazil
8.1.2 Argentina
8.1.3 Rest of Latin America
8.2 Product Type Segmentation (2017 to 2021f)
8.2.1 Finafloxacin
8.2.2 Fosfomycin Tromethamine
8.2.3 Nacubactam
8.2.4 Plazomicin Sulfate
8.2.5 Others
8.3 Consumption Segmentation (2017 to 2021f)
8.3.1 Hospital
8.3.2 Clinic
8.3.3 Others
8.4 Impact of COVID-19 in Europe
9 MIDDLE EAST AND AFRICA MARKET SEGMENTATION
9.1 Region Segmentation (2017 to 2021f)
9.1.1 GCC
9.1.2 North Africa
9.1.3 South Africa
9.1.4 Rest of Middle East and Africa
9.2 Product Type Segmentation (2017 to 2021f)
9.2.1 Finafloxacin
9.2.2 Fosfomycin Tromethamine
9.2.3 Nacubactam
9.2.4 Plazomicin Sulfate
9.2.5 Others
9.3 Consumption Segmentation (2017 to 2021f)
9.3.1 Hospital
9.3.2 Clinic
9.3.3 Others
9.4 Impact of COVID-19 in Europe
10 COMPETITION OF MAJOR PLAYERS
10.1 Brief Introduction of Major Players
10.1.1 Achaogen Inc
10.1.2 AstraZeneca Plc
10.1.3 Meiji Seika Pharma Co Ltd
10.1.4 Merck & Co Inc
10.1.5 MerLion Pharmaceuticals Pte Ltd
10.1.6 The Medicines Company
10.1.7 Zavante Therapeutics Inc
10.2 Pyelonephritis Drug Sales Date of Major Players (2017-2020e)
10.2.1 Achaogen Inc
10.2.2 AstraZeneca Plc
10.2.3 Meiji Seika Pharma Co Ltd
10.2.4 Merck & Co Inc
10.2.5 MerLion Pharmaceuticals Pte Ltd
10.2.6 The Medicines Company
10.2.7 Zavante Therapeutics Inc
10.3 Market Distribution of Major Players
10.4 Global Competition Segmentation
11 MARKET FORECAST
11.1 Forecast by Region
11.2 Forecast by Demand
11.3 Environment Forecast
11.3.1 Impact of COVID-19
11.3.2 Geopolitics Overview
11.3.3 Economic Overview of Major Countries
12 REPORT SUMMARY STATEMENT

List of Figure

List of Table
1.Table Pyelonephritis Drug Product Type Overview
2.Table Pyelonephritis Drug Product Type Market Share List
3.Table Pyelonephritis Drug Product Type of Major Players
4.Table Brief Introduction of Achaogen Inc
5.Table Brief Introduction of AstraZeneca Plc
6.Table Brief Introduction of Meiji Seika Pharma Co Ltd
7.Table Brief Introduction of Merck & Co Inc
8.Table Brief Introduction of MerLion Pharmaceuticals Pte Ltd
9.Table Brief Introduction of The Medicines Company
10.Table Brief Introduction of Zavante Therapeutics Inc
11.Table Products & Services of Achaogen Inc
12.Table Products & Services of AstraZeneca Plc
13.Table Products & Services of Meiji Seika Pharma Co Ltd
14.Table Products & Services of Merck & Co Inc
15.Table Products & Services of MerLion Pharmaceuticals Pte Ltd
16.Table Products & Services of The Medicines Company
17.Table Products & Services of Zavante Therapeutics Inc
18.Table Market Distribution of Major Players
19.Table Global Major Players Sales Revenue (Million USD) 2017-2020e
20.Table Global Major Players Sales Revenue (Million USD) Share 2017-2020e
21.Table Global Pyelonephritis Drug Market Forecast (Million USD) by Region 2021f-2026f
22.Table Global Pyelonephritis Drug Market Forecast (Million USD) Share by Region 2021f-2026f
23.Table Global Pyelonephritis Drug Market Forecast (Million USD) by Demand 2021f-2026f
24.Table Global Pyelonephritis Drug Market Forecast (Million USD) Share by Demand 2021f-2026f